New hope for Drug-Resistant ovarian cancer: targeted pill takes on chemo in phase 3 trial

NCT ID NCT07546500

Recruiting now Disease control Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Apr 24, 2026 · Last updated May 19, 2026 · Updated 6 times

Summary

This study tests a new drug called azenosertib against standard chemotherapy in people with ovarian cancer that no longer responds to platinum-based treatments. The trial includes 420 women whose tumors have a specific protein (cyclin E1). The goal is to see if azenosertib can slow cancer growth better than chemo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site 0101
RECRUITING

Torrance, California, 90505, United States
Site 0105
NOT_YET_RECRUITING

Portland, Oregon, 97210, United States
Site 0107
NOT_YET_RECRUITING

Phoenix, Arizona, 85016, United States
Site 0108
NOT_YET_RECRUITING

Columbus, Ohio, 43026, United States
Site 0109
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Site 0110
NOT_YET_RECRUITING

Antioch, California, 94531, United States
Site 0111
NOT_YET_RECRUITING

Camden, New Jersey, 08103, United States
Site 0112
NOT_YET_RECRUITING

Sioux Falls, South Dakota, 57105, United States
Site 0113
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19111, United States
Site 0114
NOT_YET_RECRUITING

Willow Grove, Pennsylvania, 19090, United States
Site 0115
NOT_YET_RECRUITING

San Francisco, California, 94109, United States
Site 0201
NOT_YET_RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Site 0202
NOT_YET_RECRUITING

Sherbrooke, Quebec, J1H 5N4, Canada
Site 0203
NOT_YET_RECRUITING

Montreal, Quebec, H2X 0C1, Canada
Site 0204
NOT_YET_RECRUITING

Montreal, Quebec, H1T 2M4, Canada
Site 1101
NOT_YET_RECRUITING

Randwick, New South Wales, 2031, Australia
Site 1102
NOT_YET_RECRUITING

Adelaide, South Australia, 5000, Australia
Site 1103
NOT_YET_RECRUITING

Nedlands, 6009, Australia
Site 1201
NOT_YET_RECRUITING

Seoul, 06351, South Korea
Site 1202
NOT_YET_RECRUITING

Seoul, 03080, South Korea
Site 1203
NOT_YET_RECRUITING

Daegu, 42601, South Korea
Site 1204
NOT_YET_RECRUITING

Seoul, 06273, South Korea
Site 1205
NOT_YET_RECRUITING

Seoul, 03722, South Korea
Site 1206
NOT_YET_RECRUITING

Goyang-si, 10408, South Korea
Site 1301
NOT_YET_RECRUITING

Taichung, 40705, Taiwan
Site 1302
NOT_YET_RECRUITING

Taipei, 11217, Taiwan
Site 3001
NOT_YET_RECRUITING

Leuven, 3000, Belgium
Site 3002
NOT_YET_RECRUITING

Brussels, 1020, Belgium
Site 3501
NOT_YET_RECRUITING

Pierre-Bénite, 69495, France
Site 3502
NOT_YET_RECRUITING

Brest, 29609, France
Site 3503
NOT_YET_RECRUITING

Paris, 75014, France
Site 3504
NOT_YET_RECRUITING

Lyon, 69373, France
Site 3505
NOT_YET_RECRUITING

Strasbourg, 67098, France
Site 3506
NOT_YET_RECRUITING

Villejuif, 94805, France
Site 3507
NOT_YET_RECRUITING

Dijon, 21079, France
Site 3508
NOT_YET_RECRUITING

Besançon, 25000, France
Site 3509
NOT_YET_RECRUITING

Saint-Herblain, 44805, France
Site 3601
NOT_YET_RECRUITING

Dresden, 01307, Germany
Site 3602
NOT_YET_RECRUITING

Berlin, D-13353, Germany
Site 3702
NOT_YET_RECRUITING

Dublin, D08 NYH1, Ireland
Site 3703
NOT_YET_RECRUITING

Cork, T12 DC4A, Ireland
Site 3801
NOT_YET_RECRUITING

Bologna, 40138, Italy
Site 3802
NOT_YET_RECRUITING

Naples, 80131, Italy
Site 3803
NOT_YET_RECRUITING

Milan, 20159, Italy
Site 3804
NOT_YET_RECRUITING

Milan, 20141, Italy
Site 3805
NOT_YET_RECRUITING

Milan, 20132, Italy
Site 3806
NOT_YET_RECRUITING

Rome, 00168, Italy
Site 3807
NOT_YET_RECRUITING

Prato, 59100, Italy
Site 4001
NOT_YET_RECRUITING

Lodz, 93-338, Poland
Site 4003
NOT_YET_RECRUITING

Szczecin, 70-111, Poland
Site 4004
NOT_YET_RECRUITING

Poznan, 61-848, Poland
Site 4006
NOT_YET_RECRUITING

Krakow, 30-348, Poland
Site 4201
NOT_YET_RECRUITING

Barcelona, 08028, Spain
Site 4202
NOT_YET_RECRUITING

Madrid, 28034, Spain
Site 4203
NOT_YET_RECRUITING

Málaga, 29011, Spain
Site 4204
NOT_YET_RECRUITING

Vigo, 36212, Spain
Site 4205
NOT_YET_RECRUITING

Barcelona, 08041, Spain
Site 4206
NOT_YET_RECRUITING

Madrid, 28040, Spain

Conditions

Explore the condition pages connected to this study.

OVARIAN CANCER